Sarah Jocelyn Fink

This inventor holds 9 USPTO granted patents and 9 published patent applications and 3 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Evrys Bio, LLC, Shire Human Genetic Therapies, Inc.. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sarah Jocelyn Fink. Retrieved from https://idiyas.com/inventor/sarah-jocelyn-fink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9 (Patent Applications = 9)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 17)

Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 18(Granted Patents)

Company Filing History:

6 out of 1,229

Takeda Pharmaceutical Company Limited

Shire Human Genetic Therapies, Inc.

patents

Years Active: 2020-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459935 - Broad spectrum antiviral compositions and methods (2025-11-04),

2. 12441724 - Inhibitors of plasma kallikrein and uses thereof (2025-10-14),

3. 12221441 - Plasma kallikrein inhibitors and uses thereof (2025-02-11),

4. 12065448 - Heteroaryl plasma kallikrein inhibitors (2024-08-20),

5. 11787796 - Plasma Kallikrein inhibitors and uses thereof (2023-10-17),

6. 11459321 - Broad spectrum antiviral compositions and methods (2022-10-04),

7. 11370803 - Heteroaryl plasma kallikrein inhibitors (2022-06-28),

8. 11352356 - Inhibitors of plasma kallikrein and uses thereof (2022-06-07),

9. 10730874 - Inhibitors of plasma kallikrein and uses thereof (2020-08-04),

Title: The Innovative Contributions of Sarah Jocelyn Fink

Introduction

Sarah Jocelyn Fink is a prominent inventor based in Arlington, MA, known for her significant contributions to the field of pharmaceutical sciences. With a total of eight patents to her name, she has made remarkable strides in developing inhibitors for plasma kallikrein, a key enzyme involved in various physiological processes.

Latest Patents

Among her latest patents are "Inhibitors of Plasma Kallikrein and Uses Thereof" and "Plasma Kallikrein Inhibitors and Uses Thereof." These inventions provide compounds and compositions that serve as effective inhibitors of plasma kallikrein, showcasing desirable characteristics for therapeutic applications. Her work in this area has the potential to impact treatments for conditions related to this enzyme.

Career Highlights

Throughout her career, Sarah has worked with notable companies such as Takeda Pharmaceutical Company Limited and Shire Human Genetic Therapies, Inc. Her experience in these organizations has allowed her to refine her expertise and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Sarah has collaborated with esteemed colleagues, including Nikolaos Papaioannou and Jeremy Mark Travins. These partnerships have fostered an environment of innovation and have led to the development of her impactful inventions.

Conclusion

In summary, Sarah Jocelyn Fink is a trailblazer in the field of pharmaceutical inventions, with a focus on plasma kallikrein inhibitors. Her contributions are paving the way for advancements in medical treatments and highlight the importance of innovation in healthcare.

Profile summary based on public USPTO records.